Variable | Characteristic | No severe swelling | Severe swelling | p-value* | Unadjusted | Adjusted | ||||
---|---|---|---|---|---|---|---|---|---|---|
n (%) | n (%) | OR | 95% CI | p-value** | OR | 95% CI | p-value*** | |||
IL-10 (pg/mL) | Median (IQR) | 5.28 (4.44; 6.32) | 5.42 (4.40; 6.37) | 0.61 | 1.04 | 0.87; 1.26 | 0.644 | Â | ND | Â |
IL-1β (pg/mL) | Median (IQR) | 2.07 (1.35; 2.77) | 2.02 (1.31; 2.58) | 0.69 | 1 | 0.79; 1.27 | 0.996 |  | ND |  |
IL-6 (pg/mL) | Median (IQR) | 5.11 (4.23; 5.95) | 5.27 (4.29; 6.38) | 0.26 | 1.11 | 0.91; 1.35 | 0.297 | Â | ND | Â |
IL-12 (pg/mL) | Median (IQR) | 2.73 (1.42; 3.20) | 3.11 (2.87; 3.29) | 0.05 | 1.37 | 0.94; 1.99 | 0.103 | 1.24 | 0.74; 2.08 | 0.415 |
IL-8 (pg/mL) | Median (IQR) | 4.27 (3.58; 5.04) | 4.46 (3.65; 5.50) | 0.16 | 1.19 | 0.93; 1.52 | 0.159 | 1.91 | 0.98; 3.71 | 0.056 |
TNF (pg/mL) | Median (IQR) | 2.82 (2.26; 3.32) | 3.03 (2.50; 3.82) | 0.07 | 1.24 | 0.95; 1.63 | 0.119 | 1.41 | 0.76; 2.76 | 0.275 |
Ratio (IL10/TNF) | Median (IQR) | 2.24 (1.32; 3.45) | 2.23 (0.85; 3.58) | 0.77 | 0.96 | 0.82; 1.13 | 0.662 | Â | ND | Â |
Ratio (IL-10/IL-6) | Median (IQR) | 0.20 (0.51; 0.85) | 0.14 (0.73; 0.77) | 0.44 | 0.9 | 0.69; 1.18 | 0.448 | Â | ND | Â |
Ratio (IL-10/IL-1β) | Median (IQR) | 3.43 (2.26; 4.51) | 3.62 (2.37; 4.46) | 0.96 | 1 | 0.83; 1.21 | 0.962 |  | ND |  |
Ratio (IL-10/IL-12) | Median (IQR) | 2.57 (1.07; 3.92) | 2.64 (0.68; 3.55) | 0.69 | 0.94 | 0.75; 1.19 | 0.632 | Â | ND | Â |
Ratio (IL-10/IL-8) | Median (IQR) | 0.96 (0.12; 1.72) | 0.92 (0.33; 1.72) | 0.67 | 0.93 | 0.76; 1.14 | 0.496 | Â | ND | Â |